Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H31NO3 |
| Molecular Weight | 357.4864 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CC#CCOC(=O)[C@@](O)(C1CCCCC1)C2=CC=CC=C2
InChI
InChIKey=XIQVNETUBQGFHX-QFIPXVFZSA-N
InChI=1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3/t22-/m0/s1
| Molecular Formula | C22H31NO3 |
| Molecular Weight | 357.4864 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Current practices in treatment of female genital fistula: a cross sectional study. | 2010-11-10 |
|
| Anesthetic management of the emergency laparotomy for a patient with multiple sclerosis -A case report-. | 2010-11 |
|
| Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. | 2010-09-14 |
|
| Urological manifestations of Chikungunya fever: A single centre experience. | 2010-09 |
|
| Posterior urethral valves: Morphological normalization of posterior urethra after fulguration is a significant factor in prognosis. | 2010-07 |
|
| Liquid Chromatographic Determination of Flavoxate HCl in Pharmaceutical Formulation. | 2010-07 |
|
| [Isolated primary nocturnal enuresis: international evidence based management. Consensus recommendations by French expert group]. | 2010-05 |
|
| Medical management of overactive bladder. | 2010-04 |
|
| Quantitative determination of oxybutynin hydrochloride by spectrophotometry, chemometry and HPTLC in presence of its degradation product and additives in different pharmaceutical dosage forms. | 2010-03-15 |
|
| Application of oxybutynin selective sensors for monitoring the dissolution profile and assay of pharmaceutical dosage forms. | 2010 |
|
| Parasympathetic functions in children with sensory processing disorder. | 2010 |
|
| No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products--a pilot study. | 2009-12-14 |
|
| Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial. | 2009-11 |
|
| Oxybutynin extended release for the management of overactive bladder: a clinical review. | 2009-09-21 |
|
| Reversible bilateral optic neuritis after Infliximab discontinuation in a patient with Crohn's disease. | 2009-09 |
|
| Polymeric matrix membrane sensors for stability-indicating potentiometric determination of oxybutynin hydrochloride and flavoxate hydrochloride urogenital system drugs. | 2009-02-11 |
|
| Behavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunction. | 2009 |
|
| Locked-in Syndrome in a Nigerian male with Multiple Sclerosis: a case report and literature review. | 2008-10-30 |
|
| Generation of an agonistic binding site for blockers of the M(3) muscarinic acetylcholine receptor. | 2008-05-15 |
|
| The neurogenic bladder: medical treatment. | 2008-05 |
|
| Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin. | 2008-02-02 |
|
| Treatment of urinary incontinence after stroke in adults. | 2008-01-23 |
|
| Bladder dysfunction and vesicoureteral reflux. | 2008 |
|
| Intravesical treatments for painful bladder syndrome/ interstitial cystitis. | 2007-10-17 |
|
| Bladder augmentation: Review of the literature and recent advances. | 2007-10 |
|
| A review of urodynamic evaluation in children and its role in the management of boys with posterior urethral valves. | 2007-10 |
|
| Primary monosymptomatic nocturnal enuresis in children and adolescents. | 2007-09 |
|
| Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. | 2007-09 |
|
| Formulation and optimization of porous osmotic pump-based controlled release system of oxybutynin. | 2007-07-13 |
|
| Analysis of pharmacological effects of drugs used for treatment of urinary disturbance based on anticholinergic and smooth muscle-relaxing effects. | 2007-07 |
|
| Pharmacokinetics/pharmacodynamics analysis of the relationship between the in vivo micturition pressure and receptor occupancy of (R)-oxybutynin and its metabolite in rats. | 2007-05 |
|
| Pharmacologic management of overactive bladder. | 2007 |
|
| New transdermal bioadhesive film containing oxybutynin: In vitro permeation across rabbit ear skin. | 2006-11-15 |
|
| Improved efficacy of extended release oxybutynin in children with persistent daytime urinary incontinence converted from regular oxybutynin. | 2006-10 |
|
| Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study. | 2006-10 |
|
| Canadian Urological Association guidelines on urinary incontinence. | 2006-06 |
|
| High performance liquid chromatographic determination of oxeladin citrate and oxybutynin hydrochloride and their degradation products. | 2005-08 |
|
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005-06 |
|
| [Urinary incontinence: anticholinergic treatment]. | 2005-04-07 |
|
| Influence of micro-environmental pH on the gel layer behavior and release of a basic drug from various hydrophilic matrices. | 2005-03-21 |
|
| A peripheric neuromodulation technique for curing detrusor overactivity: Stoller afferent neurostimulation. | 2005 |
|
| Rapid and selective UV spectrophotometric and RP-HPLC methods for dissolution studies of oxybutynin immediate-release and controlled-release formulations. | 2004-11-15 |
|
| Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review. | 2004-11 |
|
| Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder. | 2004-10 |
|
| A population pharmacokinetic model with time-dependent covariates measured with errors. | 2004-06 |
|
| Drug approval highlights for 2003. | 2004-02 |
|
| Acupressure versus oxybutinin in the treatment of enuresis. | 2004-01-08 |
|
| Oxybutynin extended-release: a review of its use in the management of overactive bladder. | 2004 |
|
| [Prevalence of urinary incontinence and linked factors in men and women over 65]. | 2003-10-15 |
|
| [Non-coordinated micturition syndrome mimicking posterior urethral valves in a male neonate]. | 2003-07 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 16:45:37 GMT 2025
by
admin
on
Wed Apr 02 16:45:37 GMT 2025
|
| Record UNII |
5BRQ29UUB7
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5BRQ29UUB7
Created by
admin on Wed Apr 02 16:45:37 GMT 2025 , Edited by admin on Wed Apr 02 16:45:37 GMT 2025
|
PRIMARY | |||
|
119618-21-2
Created by
admin on Wed Apr 02 16:45:37 GMT 2025 , Edited by admin on Wed Apr 02 16:45:37 GMT 2025
|
PRIMARY | |||
|
300000045599
Created by
admin on Wed Apr 02 16:45:37 GMT 2025 , Edited by admin on Wed Apr 02 16:45:37 GMT 2025
|
PRIMARY | |||
|
12152
Created by
admin on Wed Apr 02 16:45:37 GMT 2025 , Edited by admin on Wed Apr 02 16:45:37 GMT 2025
|
PRIMARY | |||
|
6098167
Created by
admin on Wed Apr 02 16:45:37 GMT 2025 , Edited by admin on Wed Apr 02 16:45:37 GMT 2025
|
PRIMARY | |||
|
C190351
Created by
admin on Wed Apr 02 16:45:37 GMT 2025 , Edited by admin on Wed Apr 02 16:45:37 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
RACEMATE -> ACTIVE ENANTIOMER |
|
||
|
TARGET -> INHIBITOR |
|
||
|
|
ENANTIOMER -> ENANTIOMER |
|
||
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
